ArticleBMJ open2020

Efficacy and safety of xuezhikang once per day versus two times per day in patients with mild to moderate hypercholesterolaemia (APEX study): a protocol for a multicentre, prospective randomised controlled, open-label, non-inferiority study.

Zexuan Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.